NCI-2019-08627

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC 783608) SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

This study compares giving atezolizumab, an immunotherapy drug, along with stereotactic body radiotherapy (SBRT) to using SBRT alone in patients with early-stage non-small cell lung cancer (NSCLC). Atezolizumab is a drug that helps the body's immune system fight cancer cells. Patients will be randomly assigned to two groups: one receiving atezolizumab with SBRT, and the other receiving only SBRT. Both groups will be closely monitored for treatment response and side effects.

immunotherapy: The immune system helps fight cancer by sending the body's defense (immune) system to kill the cancer cells. Immunotherapy drugs target cancer cells to prevent them from multiplying and growing.

stereotactic body radiotherapy (SBRT): a treatment method delivers strong and precise doses of radiation to cancerous tumors, aiming to get rid of cancer cells while sparing nearby healthy tissue from harm.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT04214262

Clinical Trial Site: Einstein/Sinai

To see all available clinical trials click here.